Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It

Amgen (AMGN) has recently underperformed the broader market and its industry, with shares returning only +0.5% over the past month. Despite this, the biotech giant demonstrates strong underlying fundamentals, including consistent earnings beats and positive earnings estimate revisions for the current quarter and fiscal year. Zacks rates AMGN a "Buy" (Rank #2) and assigns a Value Style Score of 'B', indicating it trades at a discount to peers, suggesting potential for near-term outperformance.

Analysis

Amgen (AMGN) presents a case of strong fundamentals currently misaligned with recent market performance. Over the past month, the stock's +0.5% return has significantly lagged the S&P 500 composite's +5% gain and has also trailed its own industry's +1% rise. Despite this price sluggishness, the company's operational performance is robust. In its last reported quarter, Amgen delivered a significant earnings surprise of +17.79% and a revenue surprise of +2.47%, with year-over-year revenue growth of +9.4%. This continues a trend of beating consensus EPS estimates for four consecutive quarters. Looking forward, estimates for the current fiscal year remain positive, with consensus forecasts pointing to +5.1% earnings growth and +5.4% revenue growth, supported by minor upward revisions over the last 30 days. However, a critical point of caution emerges from the outlook for the next fiscal year, where projected revenue and EPS growth are expected to decelerate sharply to +1.7% and +2.0%, respectively, and the consensus earnings estimate has seen a slight -0.1% negative revision. This growth slowdown contrasts with the company's favorable valuation, indicated by a Zacks Value Style Score of 'B', suggesting it trades at a discount to its peers and underpins its Zacks Rank #2 (Buy) rating for potential near-term outperformance.

Key Decisions for Investors

• Given the combination of consistent earnings outperformance and a valuation discount to peers, investors could view the recent stock underperformance as a potential entry point.
• Investors should closely monitor forward guidance for any further deterioration, as the projected deceleration in revenue and earnings growth to below 2% for the next fiscal year represents a key risk.
• The stock's favorable Zacks #2 (Buy) rating suggests near-term upside, but its lagging performance against both its industry and the broader market indicates a potential momentum disconnect that warrants consideration.